Biotech

All Articles

A nearer look at Strong Biotech's Tough 15

.In this particular full week's episode of "The Leading Pipe," our team are actually diving into Int...

Lilly faces stage 2 failure of tau-targeting med

.The confetti is still flying from Eli Lilly's celebration celebrating the commendation of Alzheimer...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of considerable leadership hirings, shootings a...

Lykos will certainly ask FDA to reconsider its own decision complying with being rejected of MDMA therapy for post-traumatic stress disorder

.Following an unsatisfactory showing for Lykos Therapeutics' MDMA candidate for trauma at a latest F...

AN 2 fifty percents roll call, quits phase 3 trial after records disappoint

.AN2 Rehabs is re-thinking its business in reaction to dull midphase data, pledging to give up half ...

Merck pays $700M for bispecific, spying autoimmune opening and opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is spending $700 thousand ahead of time to challenge Amgen in a blood cancer market....

Gilead spends J&ampJ $320M to leave licensing bargain for seladelpar

.Along With Gilead Sciences about to an FDA choice for its liver disease medicine seladelpar, the co...

' All hands on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks can observe the firms establishing camping tents at basecamp re...

Entero laying off team, moving out of office and pausing R&ampD

.Bed Liquidators has actually switched Entero Therapeutics white as a sheet. The collector purchased...

Exelixis falls ADC after determining it's no match for Tivdak

.Exelixis is giving up on its own cells variable (TF)- targeting antibody-drug conjugate after concl...